Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases

NCT05687461 | Unknown

• 1 other identifier: 12100000400014014Y
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
2. 2.Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.

Conditions

Quality Control

Keywords

Quality Control; Respiratory Diseases

Outcome Measures

Primary Outcomes (1)

• A respiratory quality control network platform has been established

  A complete national quality control network platform for the diagnosis and treatment of major respiratory diseases with multi-source data has been built

  2025.01

Study Arms (2)

People at high risk for VTE

Patients who are admitted to the hospital for acute medical illness or surgery operations.

Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases

People diagnosed with VTE

Patients who were clearly diagnosed with deep vein thrombosis or pulmonary thromboembolism.

Other: Build a national diagnosis and treatment quality control platform for major respiratory diseases

Interventions

Build a national diagnosis and treatment quality control platform for major respiratory diseases OTHER

1. Build a national diagnosis and treatment quality control platform for major respiratory diseases 2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases 3. Promotion of standardized diagnosis and treatment techniques for major respiratory diseases

People at high risk for VTE; People diagnosed with VTE

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

People at high risk of VTE, people diagnosed with VTE

You may qualify if:

• I. For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE
• \) With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism

You may not qualify if:

• I. For patients at high risk for VTE
• VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
• Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).

Sponsors & Collaborators

• China-Japan Friendship Hospital: lead

Study Sites (1)

China-Japanese Friendship Hosptial

Beijing, Beijing Municipality, 100029, China

Location

MeSH Terms

Conditions

Respiratory Tract Diseases

Study Officials

• Zhai Zhenguo, Doctor

  Department of Respiratory and Critical Care Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: December 29, 2022
• First Posted: January 18, 2023
• Study Start: July 1, 2022
• Primary Completion: December 31, 2022
• Study Completion: July 31, 2025
• Last Updated: January 18, 2023

Record last verified: 2023-01

Locations

CN (1)